Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin

References

• Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis 2000; 19: 77–88
   PubMed Web of Science ®Google Scholar
• Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its re-emergence?. Emerg Infect Dis 2001; 7: 526–8
   PubMed Web of Science ®Google Scholar
• Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994; 13: 343–5
   PubMed Web of Science ®Google Scholar
• de Melker HE, Conyn-van Spaendonck MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg Infect Dis 1997; 3: 175–8
   PubMed Web of Science ®Google Scholar
• de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Re-emergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000; 6: 348–57
   PubMed Web of Science ®Google Scholar
• Lin YC, Yao SM, Yan JJ, Chen YY, Chiang CS, Wu HS, et al. Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J Med Microbiol 2007; 56: 533–7
   PubMed Web of Science ®Google Scholar
• Mastrantonio P, Spigaglia P, van Oirschot H, van der Heide HG, Heuvelman K, Stefanelli P, et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 1999; 145: 2069–75
   PubMed Web of Science ®Google Scholar
• Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999; 67: 3133–4
   PubMed Web of Science ®Google Scholar
• Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001; 69: 5520–8
   PubMed Web of Science ®Google Scholar
• Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935–1999. J Infect Dis 2000; 182: 1402–8
   PubMed Web of Science ®Google Scholar
• Gzyl A, Augustynowicz E, Loo I, Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2001; 20: 299–303
   PubMed Web of Science ®Google Scholar
• Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 2004; 22: 2122–8
   PubMed Web of Science ®Google Scholar
• Guiso N, Boursaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M, et al. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 2001; 19: 3248–52
   PubMed Web of Science ®Google Scholar
• Kourova N, Caro V, Weber C, Thiberge S, Chuprinina R, Tseneva G, et al. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J Clin Microbiol 2003; 41: 3706–11
   PubMedGoogle Scholar
• Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997; 21: 145–8
   PubMedGoogle Scholar
• Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect 2004; 132: 185–93
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 y of age. Pediatrics 2006; 118: 978–84
   PubMed Web of Science ®Google Scholar
• Caro V, Bouchez V, Guiso N, Gatti B, Agosti MR, Ayala SE. Pertussis in Argentina and France. Vaccine 2006.
   Google Scholar
• Halperin SA. The control of pertussis–2007 and beyond. N Engl J Med 2007; 356: 110–3
   PubMed Web of Science ®Google Scholar
• Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serological correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901–6
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–16
   PubMed Web of Science ®Google Scholar
• He Q, Makinen J, Berbers G, Mooi FR, Viljanen MK, Arvilommi H, et al. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?. J Infect Dis 2003; 187: 1200–5
   PubMed Web of Science ®Google Scholar
• Hijnen M. The Bordetella pertussis protein pertactin: role in immunity and immune evasion. PhD thesis University of Utrecht, Utrecht, the Netherlands 2006.
   Google Scholar
• Hijnen M, van Gageldonk PG, Berbers GA, van Woerkom T, Mooi FR. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif 2005; 41: 106–12
   PubMed Web of Science ®Google Scholar
• Junker M, Schuster CC, McDonnell AV, Sorg KA, Finn MC, Berger B, et al. Pertactin beta-helix folding mechanism suggests common themes for the secretion and folding of autotransporter proteins. Proc Natl Acad Sci U S A 2006; 103: 4918–23
   PubMed Web of Science ®Google Scholar
• Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998; 66: 670–5
   PubMed Web of Science ®Google Scholar
• Hijnen M, Mooi FR, van Gageldonk PG, Hoogerhout P, King AJ, Berbers GA. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun 2004; 72: 3716–23
   PubMedGoogle Scholar
• Carson M, Johnson DH, McDonald H, Brouillette C, Delucas LJ. His-tag impact on structure. Acta Crystallogr D Biol Crystallogr 2007; 63: 295–301
   PubMed Web of Science ®Google Scholar